Antibody therapy of non-Hodgkin's B-cell lymphoma

Chinn, Paul; Braslawsky, Gary R.; White, Christine; Hanna, Nabil

doi:10.1007/s00262-002-0347-6

Cited by 43 publications

(16 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, various ligand-targeted therapeutics, such as immunotoxins, antibody drug-conjugates, and ligand-targeted liposomes, have been developed [12], [13], [14]. A rapidly developing class of ligand-targeted therapeutics is the ligand-targeted liposome, which combines the advantages of passive targeting (liposome) with active tumor-specific targeting (ligand) functions.…”

Section: Introductionmentioning

confidence: 99%

Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models

Chang

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

Lung cancer ranks among the most common malignancies, and is the leading cause of cancer-related mortality worldwide. Chemotherapy for lung cancer can be made more specific to tumor cells, and less toxic to normal tissues, through the use of ligand-mediated drug delivery systems. In this study, we investigated the targeting mechanism of the ligand-mediated drug delivery system using a peptide, SP5-2, which specifically binds to non-small cell lung cancer (NSCLC) cells. Conjugation of SP5-2 to liposomes enhanced the amount of drug delivered directly into NSCLC cells, through receptor-mediated endocytosis. Functional SP5-2 improved the therapeutic index of Lipo-Dox by enhancing therapeutic efficacy, reducing side effects, and increasing the survival rate of tumor-bearing mice in syngenic, metastatic and orthotopic animal models. Accumulation of SP5-2-conjugated liposomal doxorubicin (SP5-2-LD) in tumor tissues was 11.2-fold higher than that of free doxorubicin, and the area under the concentration-time curve (AUC0–72 hours) was increased 159.2-fold. Furthermore, the experiment of bioavailability was assessed to confirm that SP5-2 elevates the uptake of the liposomal drugs by the tumor cells in vivo. In conclusion, the use of SP5-2-conjugated liposomes enhances pharmacokinetic properties, improves efficacy and safety profiles, and allows for controlled biodistribution and drug release.

show abstract

Section: Introductionmentioning

confidence: 99%

Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models

Chang

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…1–2 Two RIT drugs, Zevalin® and Bexxar® are clinically available for treatment of B-cell non-Hodgkin’s lymphoma (NHL). 3–5 The RIT system generally consists of three components, a radionuclide, a tumor-targeting antibody or peptide, and a bifunctional ligand. 2,6 β-emitting radionuclides, 90 Y and 177 Lu have been extensively explored for RIT.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of ⁹⁰Y and ¹⁷⁷Lu for Targeted Radioimmunotherapy

et al. 2012

View full text Add to dashboard Cite

We report a practical and high yield synthesis of a bimodal bifunctional ligand 3p-C-NETA-NCS containing the isothiocyanate group for conjugation to a tumor targeting antibody. 3p-C-NETA-NCS was conjugated to a tumor-targeting antibody, trastuzumab, and the corresponding 3p-C-NETA-trastuzumab conjugate was evaluated and compared to trastuzumab conjugates of the known bifunctional ligands C-DOTA, C-DTPA, C-NOTA, and 3p-C-DEPA for radiolabeling kinetics with 90Y and 177Lu. 3p-C-NETA-trastuzumab conjugate exhibited extremely rapid complexation kinetics with 90Y and 177Lu. 90Y-3p-C-NETA-trastuzumab and 177Lu-3p-C-NETA-trastuzumab conjugates were stable in human serum for 2 weeks. A pilot biodistribution study was conducted to evaluate in vivo stability and tumor targeting of 177Lu-radiolabeled trastuzumab conjugate using nude mice bearing ZR-75-1 human breast cancer. 177Lu-3p-C-NETA-trastuzumab conjugate displayed low radioactivity level at blood (1.6%), low organ uptake (<2.2%), and high tumor-to-blood ratio (6.4) at 120 h. 3p-C-NETA possesses favorable in vitro and in vivo profiles and is an excellent bifunctional chelator that can be used for targeted RIT applications using 90Y and 177Lu and has potential to replace DOTA and DTPA analogues in current clinical use.

show abstract

“…Esses anticorpos anti-CD20 provaram-se capazes de induzir apoptose de células-B tumorais humanas assegurando assim sua capacidade fármaco-terapêutica [5,[7][8][9][10][11][12][13].…”

Section: Tabela 3 Antígenos Comuns Das Células-b De Lnh E Seus Anticunclassified

“…As células-B dos LNH são ideais para essa modalidade de tratamento por sua acessibilidade para os anticorpos terapêuticos, sensibilidade ao mecanismo de morte Rituximab, anticorpo anti-CD20 quimérico, específico para o antígeno CD20, Contudo, este fato salientou a importância e necessidade de uma nova abordagem de tratamento com garantias reais de alívio aos portadores desse tipo de neoplasia, a Radioimunoterapia (RIT) [9,11,12,18,19]. Radioimunoterapia é uma nova promessa de tratamento para portadores de LNH de células-B refratários ou quimioterapia recorrentes.…”

Section: Tabela 3 Antígenos Comuns Das Células-b De Lnh E Seus Anticunclassified

“…Essa abordagem consiste na combinação de princípio de tratamento sistêmico e distribuição "in loco" de radiação aos tecidos tumorais poupando os tecidos normais. Isso é realizado com uso de radioimunoconjugados -anticorpos para antígenos tumor-associados quimicamente conjugados à radionuclídeos apropriados [11,12,14,17,[19][20][21].…”

Section: Tabela 3 Antígenos Comuns Das Células-b De Lnh E Seus Anticunclassified

See 1 more Smart Citation

Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos

Akanji¹

View full text Add to dashboard Cite

Tese apresentado como parte dos requisitos para obtenção do Grau de Doutor em Ciências na Área de Tecnologia Nuclear -Aplicações. Orientadora:Dra. Elaine Bortoleti de Araújo São Paulo 2013Dedico este trabalho "in memorium" àqueles que me deu a vida, criaram e ensinaram os valores básicos, primordiais e essenciais para uma vida digna, meus queridos e amados pais; e que acima de TUDO estar DEUS, o respeito pelo próximo, pela vida e a natureza.Meus avos maternos, paternos, antepassados em geral pela cultura e princípios fundamentais na minha vida e meu viver.

show abstract

Antibody therapy of non-Hodgkin's B-cell lymphoma

Cited by 43 publications

References 109 publications

Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models

Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models

Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of ⁹⁰Y and ¹⁷⁷Lu for Targeted Radioimmunotherapy

Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos

Contact Info

Product

Resources

About

Antibody therapy of non-Hodgkin's B-cell lymphoma

Cited by 43 publications

References 109 publications

Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models

Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models

Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of 90Y and 177Lu for Targeted Radioimmunotherapy

Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos

Contact Info

Product

Resources

About

Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of ⁹⁰Y and ¹⁷⁷Lu for Targeted Radioimmunotherapy